Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | PTEN Q245* |
Gene Variant Detail | |
Relevant Treatment Approaches | Akt Inhibitor (Pan) Akt1 Inhibitor Akt2 Inhibitor PI3K Inhibitor (Pan) PIK3CB inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
PTEN Q245* | lung squamous cell carcinoma | sensitive | PI3K Inhibitor (Pan) | Buparlisib + Carboplatin + Paclitaxel | Preclinical - Pdx | Actionable | In a preclinical study, the addition of Buparlisib (BKM120) to treatment with the combination of Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in improved tumor growth inhibition compared to chemotherapy or Buparlisib (BKM120) alone in a patient-derived xenograft (PDX) model of squamous non-small cell lung cancer harboring PTEN Q245* (PMID: 39199558). | 39199558 |
PTEN Q245* | lung squamous cell carcinoma | sensitive | Carboplatin + Paclitaxel + Vistusertib | Preclinical - Pdx | Actionable | In a preclinical study, the addition of Vistusertib (AZD2014) to treatment with the combination of Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in improved tumor growth inhibition compared to chemotherapy or Buparlisib (BKM120) alone in a patient-derived xenograft (PDX) model of squamous non-small cell lung cancer harboring PTEN Q245* (PMID: 39199558). | 39199558 |